platinum has been researched along with Mesothelioma in 34 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (2.94) | 18.7374 |
1990's | 4 (11.76) | 18.2507 |
2000's | 4 (11.76) | 29.6817 |
2010's | 17 (50.00) | 24.3611 |
2020's | 8 (23.53) | 2.80 |
Authors | Studies |
---|---|
Danese, MD; Daumont, M; Gleeson, M; Lubeck, D; Nwokeji, E; Penrod, JR | 1 |
Duan, J; Jiang, Z; Zeng, X | 1 |
Asghari, AB; Chai, SM; Creaney, J; Dick, IM; Firth, T; Hansen, J; Lee, YCG; Louw, A; Lynggaard, LA; Meristoudis, C; Panou, V; Røe, OD; Szejniuk, WM; van Vliet, C; Vyberg, M | 1 |
Dunne, B; Harden, S; Hoang, W; John, T; Leal, JL; Xue, J | 1 |
Belletti, M; Bono, F; Bonomi, M; Canova, S; Carlucci, L; Ceresoli, GL; Cortinovis, DL; D'Aveni, A; De Angelis, A; De Simone, I; Galli, F; Gelsomino, F; Grosso, F; Mencoboni, M; Pasello, G; Perrino, M; Rulli, E; Zucali, PA | 1 |
Abo Elkasem, F; Bahnassy, A; Gaafer, R; Khorshid, O; Wahba, NI | 1 |
Benej, M; Bonta, M; Dome, B; Hegedus, B; Hoda, MA; Hoetzenecker, K; Klikovits, T; Laszlo, V; Limbeck, A; Megyesfalvi, Z; Nischkauer, W; Schelch, K; Szeitz, B; Tisza, A; Torok, S; Valko, Z | 1 |
Forde, PM; Reuss, JE | 1 |
Bonta, M; Holzlechner, M; Limbeck, A; Lohninger, H; Marchetti-Deschmann, M | 1 |
Ardito, R; Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Conti, B; Ghidini, A; Ghilardi, M; Petrelli, F | 1 |
Archila, P; Arrieta, O; Bacon, L; Báez, R; Campos Gómez, S; Cardona, AF; Carranza, H; Chirinos, L; Corrales, L; Cuello, M; de Lima, VCC; Freitas, HC; González, L; Granados, ST; Karachaliou, N; Martín, C; Mas, L; Núñez Cerrillo, G; Oblitas, G; Otero, J; Pérez, MA; Ramírez-Tirado, LA; Remolina Bonilla, YA; Rodriguez, J; Rojas, L; Rosell, R; Ruiz-Patiño, A; Trejo-Rosales, R; Vargas, C; Zatarain-Barrón, ZL | 1 |
Aasheim, LB; Abrahamsen, TW; Davidson, B; Dybdahl, B; Flatmark, K; Fromm, B; Hovig, E; Julsrud, L; Kristensen, AT; Larsen, SG; Lund-Andersen, C; Nakken, S; Nygård, S | 1 |
Alewine, C; Calzone, K; Churpek, JE; Desai, A; Gadiraju, M; Gao, S; Gulsuner, S; Hassan, R; Hesdorffer, M; Khan, J; Kindler, HL; King, MC; Lee, MK; Mian, I; Morrow, B; Padiernos, E; Panou, V; Patel, S; Raffeld, M; Schrump, DS; Steinberg, SM; Thomas, A; Walsh, T; Wei, JS; Xi, L; Zhang, J | 1 |
Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z | 1 |
Akca, Z; Aksahin, A; Aslan, T; Berk, V; Buyukcelik, A; Erden, A; Karaca, H; Mutlu, H; Ozkan, M | 1 |
Alessio, M; Bonarrigo, I; Gabano, E; Osella, D; Ravera, M; Zanellato, I | 1 |
Kang, YM; Lin, DJ; Liu, QH; Tian, GY; Wan, YY; Yang, SX; Yao, F; Yao, ZH | 1 |
Dyszkiewicz, W; Kalinka-Warzocha, E; Knetki-Wróblewska, M; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Powrózek, T; Ramlau, R; Winiarczyk, K | 1 |
Felley-Bosco, E; Friess, M; Frischknecht, L; Korol, D; Opitz, I; Soltermann, A; Stahel, R; Thies, S; Vrugt, B; Weder, W | 1 |
Ishida, H; Kaneko, K; Kobayashi, K; Nitanda, H; Sakaguchi, H; Yamazaki, N | 1 |
Anderson, H; Bishop, W; Lee, CW; Murray, N; Rao, SC | 1 |
Dickgreber, NJ; Fink, TH; Hossain, AM; Latz, JE; Musib, LC; Thomas, M | 1 |
Bergot, E; Lechapt, E; Zalcman, G | 1 |
Boidi, CD; Bonarrigo, I; Margiotta, N; Natile, G; Osella, D; Ostuni, R; Piccinonna, S; Zanellato, I | 1 |
Alessio, M; Bonarrigo, I; Gabano, E; Osella, D; Ravera, M; Sardi, M; Zanellato, I | 1 |
Amundsen, T; Anderssen, E; Dobra, K; Erlandsen, SE; Flatberg, A; Røe, OD; Sandeck, H; Sundstrøm, SH; Szulkin, A | 1 |
Dodič-Fikfak, M; Dolžan, V; Erčulj, N; Franko, A; Hmeljak, J; Kovač, V | 1 |
Bodis, S; Günther, D; Jung, FJ; Lardinois, D; Latkoczy, C; Opitz, I; Rentsch, K; Rousson, V; Stahel, R; Varga, Z; Vuong, V; Weder, W | 1 |
Hughes, S; O'Brien, M; Popat, S; Wilkins, A | 1 |
Bogliolo, G; Bottino, GB; Esposito, M; Lerza, R; Pannacciulli, I; Vannozzi, M | 1 |
Bernareggi, A; Castoldi, D; Cimino, G; Colombi, L; Fracasso, ME; Leone, R; Monzani, V; Soresi, E; Tedeschi, M; Usari, T | 1 |
Bogliolo, GV; Bottino, GB; Esposito, M; Fulco, RA; Lerza, R; Mencoboni, MP; Merlo, F; Pannacciulli, IM; Vannozzi, M | 1 |
Ewers, SB; Jönsson, L; Lamm, IL; Lindén, CJ; Samuelsson, L | 1 |
Issell, BF; Krikorian, JG; Lee, FH; Lopez, JA; Reich, SD; Smyth, RD | 1 |
2 review(s) available for platinum and Mesothelioma
Article | Year |
---|---|
Immunotherapy for mesothelioma: rationale and new approaches.
Topics: Antineoplastic Agents; Combined Modality Therapy; CTLA-4 Antigen; Humans; Immunotherapy; Mesothelioma; Neoplasm Proteins; Platinum; Programmed Cell Death 1 Receptor | 2020 |
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Progression-Free Survival; Treatment Outcome | 2018 |
4 trial(s) available for platinum and Mesothelioma
Article | Year |
---|---|
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Platinum; Pleural Neoplasms | 2022 |
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Pemetrexed; Phenylurea Compounds; Platinum; Pleural Neoplasms; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate | 2013 |
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dietary Supplements; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Pemetrexed; Platinum; Pleural Neoplasms; Vitamins | 2009 |
Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Interactions; Drug Therapy, Combination; Etoposide; Glutathione; Half-Life; Humans; Lung Neoplasms; Mesothelioma; Platinum; Pleural Neoplasms; Time Factors | 1992 |
28 other study(ies) available for platinum and Mesothelioma
Article | Year |
---|---|
Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Topics: Aged; Female; Humans; Male; Medicare; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Pleural Neoplasms; Retrospective Studies; United States | 2022 |
[Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neutropenia; Pemetrexed; Platinum; Pleural Neoplasms | 2022 |
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Humans; Immunohistochemistry; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Pleural Neoplasms; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2022 |
What's Current and What's New in Mesothelioma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Pleural Neoplasms | 2022 |
The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Endonucleases; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Prospective Studies; Thymidylate Synthase; Treatment Outcome | 2023 |
Laser ablation-inductively coupled plasma-mass spectrometry analysis reveals differences in chemotherapeutic drug distribution in surgically resected pleural mesothelioma.
Topics: Humans; Laser Therapy; Mass Spectrometry; Mesothelioma; Platinum | 2023 |
Multisensor Imaging-From Sample Preparation to Integrated Multimodal Interpretation of LA-ICPMS and MALDI MS Imaging Data.
Topics: Antineoplastic Agents; Cisplatin; Elements; Humans; Laser Therapy; Lipids; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Molecular Imaging; Multimodal Imaging; Multivariate Analysis; Phosphorus; Platinum; Pleura; Specimen Handling; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2018 |
Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Latin America; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Platinum; Pleural Neoplasms; Progression-Free Survival; Thoracic Surgical Procedures | 2019 |
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genetic Variation; Genomics; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Palliative Care; Pemetrexed; Peritoneal Neoplasms; Platinum; Treatment Outcome; Young Adult | 2019 |
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Repair; Female; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Platinum; Pleural Neoplasms; Survival Analysis; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Young Adult | 2019 |
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Palliative Care; Pemetrexed; Platinum; Pleural Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mesothelioma; Platinum; Pleural Neoplasms | 2013 |
Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Platinum; Pleural Neoplasms; Prognosis; Proportional Hazards Models; Serum Albumin | 2014 |
Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Glutamates; Guanine; Humans; Male; Mesothelioma; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Mutagenesis, Insertional; Pemetrexed; Pharmacogenetics; Platinum; Pleural Neoplasms; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Analysis; Tandem Repeat Sequences; Thymidylate Synthase; Treatment Outcome | 2014 |
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nestin; Pemetrexed; Platinum; Pleural Neoplasms; Pneumonectomy; Prognosis; Sarcoma; Stem Cell Factor | 2015 |
Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
Topics: Adult; Aged; Cisplatin; Female; Humans; Hyperthermia, Induced; Infusions, Intralesional; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Perfusion; Platinum; Pleural Cavity; Pleural Effusion, Malignant; Pleural Neoplasms; Prospective Studies; Thoracic Surgery, Video-Assisted | 2017 |
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Cisplatin; Clinical Trials, Phase II as Topic; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Platinum; Pleural Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?
Topics: Antineoplastic Agents; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Platinum; Pleural Neoplasms | 2011 |
Platinum-bisphosphonate complexes have proven to be inactive chemotherapeutics targeted for malignant mesothelioma because of inappropriate hydrolysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diphosphonates; Humans; Hydrolysis; Ligands; Mesothelioma; Platinum; Spectrometry, Mass, Electrospray Ionization | 2011 |
Evaluation of platinum-ethacrynic acid conjugates in the treatment of mesothelioma.
Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Coordination Complexes; Drug Evaluation, Preclinical; Ethacrynic Acid; Glutathione; Glutathione Transferase; Humans; Mesothelioma; Platinum | 2011 |
Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
Topics: 5'-Nucleotidase; Adult; Antineoplastic Agents; Biopsy; Cell Adhesion; Cohort Studies; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genome-Wide Association Study; Glutamates; Guanine; Humans; Immunohistochemistry; Mesothelioma; Oligonucleotide Array Sequence Analysis; Pemetrexed; Platinum; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Cycle Proteins; Deoxycytidine; DNA; DNA Repair; DNA-Binding Proteins; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Nuclear Proteins; Peritoneal Neoplasms; Platinum; Pleural Effusion, Malignant; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Rad51 Recombinase; Survival Rate; X-ray Repair Cross Complementing Protein 1 | 2012 |
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma.
Topics: Administration, Topical; Animals; Antineoplastic Agents; Cisplatin; Drug Carriers; Fibrin Tissue Adhesive; Immunocompetence; Mesothelioma; Platinum; Pleura; Pleural Neoplasms; Rats; Rats, Inbred F344 | 2006 |
Malignant pleural mesothelioma: two cases in first degree relatives.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Family; Humans; Male; Mesothelioma; Middle Aged; Platinum; Pleural Neoplasms; Tomography, X-Ray Computed | 2007 |
High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
Topics: Absorption; Cisplatin; Drug Administration Schedule; Drug Tolerance; Feasibility Studies; Humans; Injections; Male; Mesothelioma; Middle Aged; Platinum; Pleura; Pleural Effusion, Malignant; Pleural Neoplasms; Remission Induction | 1994 |
Regional pharmacokinetic selectivity of intrapleural cisplatin.
Topics: Aged; Cisplatin; Female; Humans; Male; Mesothelioma; Platinum; Pleura; Pleural Neoplasms | 1991 |
Electrolysis with different electrode materials and combined with irradiation for treatment of experimental rat tumors.
Topics: Animals; Colonic Neoplasms; Combined Modality Therapy; Copper; Electrodes, Implanted; Electrolysis; Mesothelioma; Neoplasm Transplantation; Neoplasms, Experimental; Platinum; Rats; Rats, Inbred WF; Rats, Nude; Rhodium; Zinc | 1991 |
Clinical pharmacology of intraperitoneal cisplatin.
Topics: Aged; Ascitic Fluid; Cisplatin; Drug Evaluation; Female; Humans; Injections, Intraperitoneal; Kinetics; Mesothelioma; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Spectrophotometry, Atomic | 1985 |